用于糖尿病治疗的葡萄糖响应性微针贴片
Glucose-Responsive Microneedle Patches for Diabetes Treatment.
作者信息
Chen Guojun, Yu Jicheng, Gu Zhen
机构信息
1 Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA.
2 Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
出版信息
J Diabetes Sci Technol. 2019 Jan;13(1):41-48. doi: 10.1177/1932296818778607. Epub 2018 May 31.
Antidiabetic therapeutics, including insulin as well as glucagon-like peptide 1 (GLP-1) and its analogs, are essential for people with diabetes to regulate their blood glucose levels. Nevertheless, conventional treatments based on hypodermic administration is commonly associated with poor blood glucose control, a lack of patient compliance, and a high risk of hypoglycemia. Closed-loop drug delivery strategies, also known as self-regulated administration, which can intelligently govern the drug release kinetics in response to the fluctuation in blood glucose levels, show tremendous promise in diabetes therapy. In the meantime, the advances in the development and use of microneedle (MN)-array patches for transdermal drug delivery offer an alternative method to conventional hypodermic administration. Hence, glucose-responsive MN-array patches for the treatment of diabetes have attracted increasing attentions in recent years. This review summarizes recent advances in glucose-responsive MN-array patch systems. Their opportunities and challenges for clinical translation are also discussed.
抗糖尿病疗法，包括胰岛素以及胰高血糖素样肽1（GLP-1）及其类似物，对于糖尿病患者调节血糖水平至关重要。然而，基于皮下给药的传统治疗通常与血糖控制不佳、患者依从性差以及低血糖风险高有关。闭环给药策略，也称为自我调节给药，能够根据血糖水平的波动智能地控制药物释放动力学，在糖尿病治疗中显示出巨大的前景。与此同时，用于透皮给药的微针（MN）阵列贴片的开发和应用进展为传统皮下给药提供了一种替代方法。因此，用于治疗糖尿病的葡萄糖响应性MN阵列贴片近年来受到了越来越多的关注。本文综述了葡萄糖响应性MN阵列贴片系统的最新进展。还讨论了它们在临床转化方面的机遇和挑战。
Zotero 插件